For many individuals living with depression, traditional antidepressants can provide relief. However, some experience minimal or inadequate improvement despite trying multiple medications. This is known as treatment-resistant depression (TRD)—a challenging and often overwhelming reality. At Foveo Healthcare A Professional Medical Corporation, our mission is to offer effective, evidence-based treatments that empower patients to regain control of their mental health. One of the most innovative options available today is Spravato® (esketamine) nasal spray.
What Is Spravato®?
Spravato® is an FDA-approved esketamine nasal spray specifically designed to address moderate to severe treatment-resistant depression in adults. Unlike traditional antidepressants that target neurotransmitters like serotonin and norepinephrine, Spravato® works on the glutamate system, which plays a critical role in neural activation, mood regulation, and synaptic plasticity.
This unique mechanism allows Spravato® to bring relief more rapidly than standard antidepressants—often within hours to days, rather than weeks.
How Spravato® Works
Spravato® is administered in a comfortable, controlled medical office environment under the supervision of trained healthcare professionals. During treatment:
- The patient self-administers the nasal spray in the clinic.
- They remain onsite for approximately two hours for monitoring.
- A healthcare provider evaluates the patient before discharge.
This structured treatment environment ensures safety and allows patients to relax while the medication takes effect.
Who Is a Candidate for Spravato®?
Spravato® may be recommended for patients who:
- Have tried two or more antidepressants without sufficient improvement
- Struggle with persistent, life-disrupting depressive symptoms
- Need faster-acting relief compared to traditional medications
- Are being treated for major depressive disorder (MDD) with acute suicidal ideation (per specific FDA indications)
Eligibility is determined through a thorough evaluation by our mental health professionals.
Benefits of Spravato®
1. Rapid Relief
Many patients report improvement within their first few treatments—much faster than typical antidepressants.
2. Novel Mechanism of Action
Spravato® targets glutamate pathways, offering hope to individuals who haven’t responded to serotonin-based treatments.
3. Administered in a Safe, Supportive Environment
Treatment occurs in a monitored medical setting, ensuring optimal comfort and safety.
4. Paired with Oral Antidepressants
Using Spravato® alongside an oral antidepressant enhances therapeutic benefit.
Is Spravato® Safe?
Spravato® is FDA-approved and proven effective in multiple clinical trials. Common side effects may include:
- Dizziness
- Nausea
- Dissociation
- Fatigue
- Temporary increases in blood pressure
These effects usually resolve within the monitored recovery period. The treatment is provided in a regulated environment to ensure patient stability and comfort.
Spravato® Q&A: Your Most Important Questions Answered
Q: How quickly does Spravato® work?
Many patients notice mood improvements within 24–72 hours after the first few sessions. Responses vary, but Spravato® is known for its rapid onset.
Q: How often are treatments scheduled?
The typical schedule includes:
- Weeks 1–4: Twice weekly
- Weeks 5–8: Once weekly
- Weeks 9 and beyond: Once weekly or every other week, depending on response
Your provider will personalize a plan to maximize benefit.
Q: Can I drive after my treatment?
No. You must arrange transportation home after each session because Spravato® can cause temporary sedation and dissociation.
Q: Does insurance cover Spravato®?
Many insurance providers—including Medicare—may cover Spravato® for eligible patients. Our team can assist with verifying benefits and navigating prior authorizations.
Q: How is Spravato® different from ketamine infusions?
Both treatments involve ketamine-class compounds, but:
- Spravato® is FDA-approved
- It is covered by many insurance plans
- It is administered as a nasal spray
- It must be taken in combination with an oral antidepressant
Q: What should I expect during my visit?
A typical appointment includes:
- Pre-treatment assessment
- Self-administered nasal spray under supervision
- A quiet two-hour monitoring period
- A post-treatment evaluation before leaving
Patients often describe the experience as relaxing and supportive.
Q: Is Spravato® addictive?
When used as prescribed in a controlled setting, Spravato® has minimal risk of addiction. Treatments occur only in-office and are closely supervised.
Take the Next Step Toward Renewed Mental Wellness
Depression can feel isolating, but effective help is available. If you or a loved one is struggling with treatment-resistant depression, our compassionate team at Foveo Healthcare A Professional Medical Corporation is here to guide you through your options and help determine whether Spravato® may be appropriate.
Contact Us
Foveo Healthcare A Professional Medical Corporation
500 E Olive Ave, Suite 440
Burbank, CA 91501
Phone: (818) 254-9967
Appointments: https://foveohealthcare.com/appointments/
For more information on health and wellness services, please reach out to us.
Your journey toward better mental health starts with a single step—and we’re here to support you every step of the way.
Source of Treatment Information / Best Practices
All clinical, safety, and usage information for Spravato® (esketamine) is sourced directly from the manufacturer’s FDA-approved prescribing information provided by Janssen Pharmaceuticals. Additional supporting details reflect guidance from the U.S. Food and Drug Administration (FDA) and reputable clinical resources such as the American Psychiatric Association and the National Institute of Mental Health (NIMH).
As a best practice, all treatment information provided by Foveo Healthcare A Professional Medical Corporation is based on official manufacturer documentation, FDA regulatory materials, or peer-reviewed clinical guidelines.